Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42574 | 34133256 | Expert Rev Mol Diagn | Dysregulation of lncRNA-H19 in cardiometabolic diseases and the molecular mechanism involved : a systematic review. | 2021 | Details |
| A42576 | 34127524 | Gut | Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A42599 | 34058408 | Clin Gastroenterol Hepatol | Sugar-sweetened Beverages Are Associated With Increased Liver Stiffness and Steatosis Among Apparently Healthy Adults in the United States. | 2021 | Details |
| A42607 | 34035697 | Gastroenterol Hepatol (N Y) | Smoking and Liver Disease. | 2020 | Details |
| A42620 | 33989632 | Metabolism | Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe? | 2021 | Details |
| A42621 | 33987426 | Ann Transl Med | It's all about the spaces between cells: role of extracellular matrix in liver fibrosis. | 2021 | Details |
| A42623 | 33985820 | J Hepatol | FXR agonists for NASH: How are they different and what difference do they make? | 2021 | Details |
| A42639 | 33932057 | Transpl Int | Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! | 2021 | Details |
| A42640 | 33930552 | Clin Gastroenterol Hepatol | Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals. | 2021 | Details |
| A42642 | 33919641 | Diagnostics (Basel) | Associations between Pre-Bariatric High-Sensitivity C-Reactive Protein and Post-Surgery Outcomes. | 2021 | Details |
| A42699 | 33724502 | Hepatology | Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD. | 2021 | Details |
| A42700 | 33724489 | Hepatology | Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis. | 2021 | Details |
| A42705 | 33709605 | J Gastroenterol Hepatol | Artificial intelligence in liver disease. | 2021 | Details |
| A42712 | 33674915 | J Gen Intern Med | Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. | 2021 | Details |
| A42717 | 33654016 | Curr Opin Gastroenterol | Statins for treatment of chronic liver disease. | 2021 | Details |
| A42718 | 33653988 | Eur J Gastroenterol Hepatol | The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. | 2021 | Details |
| A42723 | 33642147 | J Diabetes Complications | Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. | 2021 | Details |
| A42726 | 33638026 | Mol Cell Biochem | Endoplasmic reticulum stress and autophagy are involved in adipocyte-induced fibrosis in hepatic stellate cells. | 2021 | Details |
| A42737 | 33603515 | Risk Manag Healthc Policy | MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. | 2021 | Details |
| A42750 | 33584986 | World J Hepatol | Autophagy in liver diseases. | 2021 | Details |
| A42763 | 33545720 | Planta Med | Bioaccessibility and Absorption of Flavonoid C-glycosides from Abrus mollis Using Simulated Digestion, Caco-2 Cell, and In Situ Single-pass Perfusion Models. | 2021 | Details |
| A42772 | 33522247 | J Am Heart Assoc | Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1. | 2021 | Details |
| A42773 | 33515802 | Ann Hepatol | Reply to: Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. | 2021 | Details |
| A42775 | 33509738 | Dig Liver Dis | Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?" | 2021 | Details |
| A42786 | 33483258 | Dig Liver Dis | Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk? | 2021 | Details |
| A42799 | 33445170 | J Clin Invest | Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. | 2021 | Details |
| A42800 | 33442020 | Nat Rev Gastroenterol Hepatol | Full-spectrum transcriptomics in NAFLD. | 2021 | Details |
| A42812 | 33385572 | Ann Hepatol | Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. | 2020 | Details |
| A42814 | 33377648 | Clin Transl Med | Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling. | 2017 | Details |
| A42815 | 33359898 | J Hepatol | Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". | 2020 | Details |
| A42820 | 33347955 | Mol Cell Endocrinol | RORα regulates hepatic lipolysis by inducing transcriptional expression of PNPLA3 in mice. | 2020 | Details |
| A42828 | 33340576 | J Hepatol | The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD. | 2020 | Details |
| A42830 | 33340573 | J Hepatol | Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. | 2020 | Details |
| A42846 | 33308438 | Lancet Gastroenterol Hepatol | Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. | 2021 | Details |
| A42847 | 33308437 | Lancet Gastroenterol Hepatol | Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. | 2021 | Details |
| A42852 | 33283299 | Hepatology | Microbiome Biomarkers: One Step Closer in NAFLD Cirrhosis. | 2021 | Details |
| A42857 | 33280151 | Hepatology | NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions. | 2021 | Details |
| A42860 | 33274619 | Pol Arch Intern Med | An elevated Fibrosis-4 score is associated with poor clinical outcomes in patients with sepsis: an observational cohort study. | 2020 | Details |
| A42861 | 33274438 | Hepatology | Letter to the Editor: ABIDE Model for Predicting Decompensation in Nonalcoholic Fatty Liver Disease-Related Cirrhosis. | 2021 | Details |
| A42862 | 33267571 | Minerva Gastroenterol (Torino) | Liver fibrosis in NAFLD patients: examining the opportunity to find a non-invasive, accurate and low-cost tool. | 2020 | Details |
| A42868 | 33249727 | Liver Int | Low skeletal muscle mass and significant fibrosis in non-alcoholic fatty liver disease: Cause or effect? | 2020 | Details |
| A42883 | 33217094 | Liver Int | Reply to: Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. | 2020 | Details |
| A42884 | 33205875 | Aliment Pharmacol Ther | Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Authors' reply. | 2020 | Details |
| A42885 | 33205873 | Aliment Pharmacol Ther | Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. | 2020 | Details |
| A42888 | 33190748 | Clin Gastroenterol Hepatol | Use of FibroScan-AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US Veterans. | 2020 | Details |
| A42895 | 33176064 | Liver Int | The association of low-grade albuminuria with incident nonalcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycemic status. | 2020 | Details |
| A42896 | 33164861 | Metabolism | Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. | 2020 | Details |
| A42911 | 33125345 | Aging (Albany NY) | MerTK, a risk factor for NASH fibrosis. | 2020 | Details |
| A42920 | 33089485 | Dig Dis Sci | Arrested Development: Slow Progression of Fibrosis in Patients with NAFLD and IBD. | 2020 | Details |
| A42927 | 33068450 | Liver Int | Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. | 2021 | Details |
| A42929 | 33053354 | Cell Rep | Prostaglandin E2-EP4 Axis Promotes Lipolysis and Fibrosis in Adipose Tissue Leading to Ectopic Fat Deposition and Insulin Resistance. | 2020 | Details |
| A42936 | 33034103 | Liver Int | The association of low-grade albuminuria with incident nonalcoholic fatty liver disease and non-invasive markers of liver fibrosis. | 2021 | Details |
| A42946 | 32994080 | J Hepatol | Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease. | 2020 | Details |
| A42950 | 32981752 | J Hepatol | Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". | 2020 | Details |
| A42951 | 32980092 | Semin Ultrasound CT MR | Pearls and Pitfalls of Metabolic Liver Magnetic Resonance Imaging in the Pediatric Population. | 2020 | Details |
| A42960 | 32951911 | J Hepatol | Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease". | 2020 | Details |
| A42962 | 32944995 | J Gastroenterol Hepatol | Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease? | 2020 | Details |
| A42967 | 32932282 | Chin Med J (Engl) | Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. | 2020 | Details |
| A42978 | 32899741 | Life (Basel) | Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study. | 2020 | Details |
| A42980 | 32895142 | Nan Fang Yi Ke Da Xue Xue Bao | [Gut microbiota-an important contributor to liver diseases]. | 2020 | Details |
| A42983 | 32890593 | J Hepatol | The times they are a-changin' (for NAFLD as well). | 2020 | Details |
| A42991 | 32876833 | Eur Radiol | Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. | 2020 | Details |
| A42994 | 32869840 | Clin Infect Dis | Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. | 2021 | Details |
| A42997 | 32860090 | Dig Dis Sci | Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. | 2020 | Details |
| A42999 | 32853777 | Ann Hepatol | For fatty liver diseases, it is time to utilize non-invasive fibrosis tests to predict liver related events rather than just histological stages of hepatic fibrosis! | 2020 | Details |
| A43002 | 32845785 | J Interferon Cytokine Res | Key Players of Hepatic Fibrosis. | 2020 | Details |
| A43004 | 32832515 | Hepatobiliary Surg Nutr | The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. | 2020 | Details |
| A43028 | 32768596 | Gastroenterology | Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis. | 2020 | Details |
| A43030 | 32763241 | Gastroenterology | Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. | 2020 | Details |
| A43031 | 32759301 | Gut | NAFLD between genes and environment: what drives fibrogenesis? | 2020 | Details |
| A43033 | 32757393 | Hepatology | Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights. | 2020 | Details |
| A43044 | 32707055 | Metabolism | Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). | 2020 | Details |
| A43045 | 32702498 | Ann Hepatol | Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. | 2020 | Details |
| A43052 | 32694177 | Gut | Diet-refractory NASH in an elderly woman. | 2020 | Details |
| A43053 | 32693115 | J Ethnopharmacol | A review of the processed Polygonum multiflorum (Thunb.) for hepatoprotection: Clinical use, pharmacology and toxicology. | 2020 | Details |
| A43054 | 32692117 | J Clin Gastroenterol | Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43059 | 32680469 | BMC Gastroenterol | Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis. | 2020 | Details |
| A43061 | 32668489 | J Viral Hepat | Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. | 2020 | Details |
| A43070 | 32643632 | Indian J Dermatol Venereol Leprol | Metabolic syndrome and female gender, but not methotrexate, are the important associations of significant liver fibrosis in patients with moderate-to-severe psoriasis as detected by transient elastography. | 2021 | Details |
| A43073 | 32626927 | Mol Med Rep | TLR4 mediates inflammation and hepatic fibrosis induced by chronic intermittent hypoxia in rats. | 2020 | Details |
| A43107 | 32553811 | Eur J Pharmacol | The effect of emodin on liver disease -- comprehensive advances in molecular mechanisms. | 2020 | Details |
| A43147 | 32424931 | Aliment Pharmacol Ther | Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply. | 2020 | Details |
| A43148 | 32424927 | Aliment Pharmacol Ther | Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. | 2020 | Details |
| A43150 | 32424917 | Aliment Pharmacol Ther | Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? | 2020 | Details |
| A43152 | 32423633 | J Hepatol | Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward". | 2020 | Details |
| A43154 | 32416974 | J Hepatol | Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward. | 2020 | Details |
| A43155 | 32414813 | Gut | Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. | 2020 | Details |
| A43157 | 32410996 | Front Pharmacol | Paeoniflorin, a Natural Product With Multiple Targets in Liver Diseases-A Mini Review. | 2020 | Details |
| A43161 | 32395243 | Clin Liver Dis (Hoboken) | Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43169 | 32382265 | Gastroenterol Res Pract | Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. | 2020 | Details |
| A43172 | 32376412 | Gastroenterology | Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. | 2020 | Details |
| A43177 | 32360996 | J Hepatol | STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. | 2020 | Details |
| A43190 | 32338785 | Aliment Pharmacol Ther | Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? | 2020 | Details |
| A43191 | 32338780 | Aliment Pharmacol Ther | Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply. | 2020 | Details |
| A43216 | 32272823 | Minerva Gastroenterol (Torino) | One-minute liver "digitopsy" for point of care risk stratification of fibrosis in nonalcoholic fatty liver disease. | 2020 | Details |
| A43221 | 32258950 | Hepatol Commun | Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. | 2020 | Details |
| A43226 | 32245907 | Gut | Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. | 2020 | Details |
| A43233 | 32222994 | Hepatology | Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression? | 2020 | Details |
| A43234 | 32222527 | Exp Parasitol | The acute schistosomiasis mansoni ameliorates metabolic syndrome in the C57BL/6 mouse model. | 2020 | Details |
| A43235 | 32220903 | Gut | Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts? | 2020 | Details |